Patients diagnosed of COVID-19 disease are randomized to receive a single dose of 100.000 IU of Cholecalciferol (Vitamin D arm) or no vitamin D (on top of the current medication used to treat COVID 19). Clinical, radiological and biochemical outcomes of COVID 19 disease as well as mortality are evaluated.
Efficacy parameters to compare both groups (vitamin D and No vitamin D).
Time to reach undetectable levels of SARS COV2 Infection.
Time of normalization of symptoms and clinical parameters.
Time of normalization of radiological images.
Time of normalization of biochemical markers.
Time of normalization of molecular inflammatory markers.
Transfer to the Intensive care Unit.
Mortality rate.
Drug: Cholecalciferol
Single doe of 100.000 IU
Other Name: Vitamin D
Inclusion Criteria:
- > 18 year
- Diagnosis of COVID-19
- Accept to participate in the study ( consent)
Exclusion Criteria:
- Pregnancy
- Allergy to vitamin D
- Consumption of any form of vitamin D during the last 3 months
- Expected fatal outcome in the next 24 hours
- Cognitive deterioration
Hospital Universitario Central de Asturias
Oviedo, Asturias, Spain
Investigator: Jorge B Cannata-Andía, MD PhD
Contact: *34 985106137
cannata@hca.es
Jorge B Cannata-Andía, MD PhD
*34 985 106137
cannata@hca.es
Juan Pérez-Ortega
*34 985109905
juan.perez@finba.es